Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 8 Multiple Myeloma 4 Glioma 4 Thyroid Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Lymphoma 2 Lung Neoplasms 2 Hematologic Neoplasms 2 Glioblastoma 2 Colorectal Neoplasms 2 Astrocytoma 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Stomach Neoplasms 1 Spinocerebellar Degenerations 1 Sarcoma 1 Refractory Differentiated Thyroid Gland Carcinoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Neurofibromatosis 1 1 Neurofibroma, Plexiform 1 Neurocytoma 1 Neuroblastoma 1 Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1

Interventions

Doxorubicin 13 Specimen Handling 12 pembrolizumab 11 Magnetic Resonance Spectroscopy 10 Biopsy 10 Cyclophosphamide 9 X-Rays 7 Ifosfamide 7 Radiotherapy 6 Phantoms, Imaging 6 Gemcitabine 6 liposomal doxorubicin 5 Nivolumab 5 tazemetostat 4 palbociclib 4 fludarabine 4 atezolizumab 4 Temozolomide 4 Radiation 4 Nuclear Medicine Department, Hospital 4 Irinotecan 4 larotrectinib 3 cabozantinib 3 Surveys and Questionnaires 3 Ipilimumab 3 Carboplatin 3 Bevacizumab 3 ulixertinib 2 tipifarnib 2 selpercatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × dabrafenib × 90 days × Clear all

NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡